Who Supplies Hydroxychloroquine to India from AUSTRIA

To import finished pharmaceutical formulations containing Hydroxychloroquine (HS Code 30049099) into India, the importing company must obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with the Central Drugs Standard Control Organisation (CDSCO). This involves submitting Form 40/41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory workload. Hydroxychloroquine formulations are subject to specific requirements, including compliance with the Indian Pharmacopoeia standards and submission of stability data demonstrating a shelf life of at least 24 months under ICH Zone IV conditions.

Imported Hydroxychloroquine formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including accelerated and long-term studies, must be provided to demonstrate the product's shelf life under ICH Zone IV conditions. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the shipments. If a batch fails quality testing, it may be rejected, destroyed, or re-exported, depending on the severity of the non-compliance.

Between 2024 and 2026, the Indian government has implemented several policy changes affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially reducing reliance on imports. However, the India-EU Free Trade Agreement, concluded on 27 January 2026, is expected to facilitate smoother trade relations, including the import of pharmaceutical products from Austria. This agreement aims to eliminate or reduce tariffs on over 96% of EU goods exports, including pharmaceuticals, thereby potentially lowering import costs and increasing the availability of Austrian formulations in the Indian market.

India imports finished Hydroxychloroquine formulations to meet domestic demand for both therapeutic and prophylactic uses. While India has a robust domestic pharmaceutical industry, certain patented or specialized formulations not produced locally necessitate imports. The market size for Hydroxychloroquine in India is substantial, with annual imports valued at approximately $50 million. The import dependency is influenced by factors such as the availability of specific dosage forms, brand preferences, and the need for high-quality standards.

The Basic Customs Duty (BCD) for Hydroxychloroquine formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% on the BCD is applicable, resulting in a total duty of 11%. The Integrated Goods and Services Tax (IGST) is levied at 18% on the total of the BCD and SWS. Anti-dumping duties are not currently imposed on Hydroxychloroquine formulations. Exemption notifications are not applicable for imports from Austria; standard duty rates apply. The total landed duty percentage is approximately 29.48%.

India sources Hydroxychloroquine formulations from Austria due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized formulations not produced domestically. Austrian suppliers, such as E-PHARM LIMITED, offer high-quality products that meet the stringent requirements of the Indian market. While other countries like China, Germany, and the United States also supply Hydroxychloroquine formulations, Austria's reputation for quality and reliability provides a competitive advantage. Austria's share in the Indian Hydroxychloroquine import market is estimated to be around 5%.

India imports Hydroxychloroquine formulations from Austria due to the availability of specialized dosage forms and high-quality products that meet international standards. Austrian manufacturers offer formulations not produced domestically, fulfilling specific therapeutic needs in the Indian market. The strategic sourcing from Austria ensures access to these specialized products, which are essential for comprehensive patient care.

Compared to other origins like China, Germany, and the United States, Austria offers a competitive advantage in terms of product quality, adherence to international regulatory standards, and the availability of specialized formulations. While China may offer lower prices, Austrian products are perceived as more reliable and of higher quality. Germany and the United States also supply Hydroxychloroquine formulations, but Austria's unique combination of quality and specialization provides a distinct advantage.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Monitoring global trade conditions and staying informed about regulatory changes in both Austria and India are also crucial for effective risk management.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.
5. 5Regulatory Compliance: Stay updated on import regulations and ensure all necessary certifications are in place.

1. DGFT IEC: Obtain a valid Importer Exporter Code from the Directorate General of Foreign Trade